Acrivon Therapeutics

Q2 FY2026 EarningsQ2 FY26 beat consensus across bottom-line metrics: Net loss of $18.0M was narrower than the expected $20.3M, and EPS (GAAP) of -$0.43 beat the -$0.50 estimate. Revenue remained at $0.0M in line with expectations for this clinical-stage biotech. The beat was driven by lower-than-expected R&D and G&A expenses due to the timing of clinical programs and non-recurring 2025 milestones, extending the cash runway into Q4 2027.